The "North America RNA Therapeutics Market, By Country, Competition, Forecast & Opportunities, 2019-2029F" report has been ...

Jefferies analyst Michael Yee assigned a Buy rating to Viridian Therapeutics (VRDN – Research Report) today and set a price target of ...

Headquartered in Cambridge, Massachusetts, Moderna, Inc. (MRNA) is a biotechnology company specializing in messenger RNA ...

(NASDAQ:MRNA) today announced it was ranked the number one large employer in BioSpace's 2025 Best Places to Work report based on the Company's reputation and commitment to innovation. 'We are honored ...

PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) has announced its financial results for the third quarter of 2024 ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

Bank of America Securities analyst Alec Stranahan reiterated a Hold rating on Moderna (MRNA – Research Report) today and set a price ...

The in vivo cell therapy seed Carisma Therapeutics planted with Moderna in 2022 is starting to sprout. | The in vivo cell ...

Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global ...

Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its ...